{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T15:03:48Z","timestamp":1770908628820,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T00:00:00Z","timestamp":1526688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"European Regional Development Fund (NORTE2020)","award":["NORTE-01-0145-FEDER-000003"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000003"]}]},{"name":"European Regional Development Fund (NORTE2020)","award":["NORTE-01-0145-FEDER-000029"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000029"]}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["POCI-01-0145-FEDER-007274"],"award-info":[{"award-number":["POCI-01-0145-FEDER-007274"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/BIM-MEC\/2834\/2014"],"award-info":[{"award-number":["PTDC\/BIM-MEC\/2834\/2014"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["IF\/00615\/2013"],"award-info":[{"award-number":["IF\/00615\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia (PT)","award":["SFRH\/BPD\/89764\/2012"],"award-info":[{"award-number":["SFRH\/BPD\/89764\/2012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10120-018-0836-8","type":"journal-article","created":{"date-parts":[[2018,5,19]],"date-time":"2018-05-19T01:03:19Z","timestamp":1526691799000},"page":"77-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression"],"prefix":"10.1007","volume":"22","author":[{"given":"Irene","family":"Gullo","sequence":"first","affiliation":[]},{"given":"Patr\u00edcia","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Athelogou","sequence":"additional","affiliation":[]},{"given":"Gilza","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Marta L.","family":"Pinto","sequence":"additional","affiliation":[]},{"given":"Joana","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Valente","sequence":"additional","affiliation":[]},{"given":"Hugo","family":"Pinheiro","sequence":"additional","affiliation":[]},{"given":"Sara","family":"Andrade","sequence":"additional","affiliation":[]},{"given":"Gabriela M.","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Ralf","family":"Huss","sequence":"additional","affiliation":[]},{"given":"Kakoli","family":"Das","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Tan","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 C.","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Carla","family":"Oliveira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-1006","authenticated-orcid":false,"given":"F\u00e1tima","family":"Carneiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,5,19]]},"reference":[{"key":"836_CR1","unstructured":"Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. 2012. \n                    http:\/\/www.globocaniarcfr\n                    \n                  . Accessed 01 Feb 2017."},{"issue":"2","key":"836_CR2","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1053\/j.gastro.2011.04.042","volume":"141","author":"IB Tan","year":"2011","unstructured":"Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology. 2011;141(2):476\u201385. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2011.04.042\n                    \n                  .","journal-title":"Gastroenterology"},{"issue":"3","key":"836_CR3","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00428-013-1533-y","volume":"464","author":"C Duraes","year":"2014","unstructured":"Duraes C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch. 2014;464(3):367\u201378. \n                    https:\/\/doi.org\/10.1007\/s00428-013-1533-y\n                    \n                  .","journal-title":"Virchows Arch"},{"issue":"9742","key":"836_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(10)61121-x\n                    \n                  .","journal-title":"Lancet"},{"issue":"9911","key":"836_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31\u20139. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(13)61719-5\n                    \n                  .","journal-title":"Lancet"},{"issue":"11","key":"836_CR6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(14)70420-6\n                    \n                  .","journal-title":"Lancet Oncol"},{"issue":"5","key":"836_CR7","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","volume":"16","author":"C Ralph","year":"2010","unstructured":"Ralph C, Elkord E, Burt DJ, O\u2019Dwyer JF, Austin EB, Stern PL, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(5):1662\u201372. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-2870\n                    \n                  .","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"6","key":"836_CR8","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717\u201326. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(16)00175-3\n                    \n                  .","journal-title":"Lancet Oncol"},{"key":"836_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejca.2016.02.020","volume":"59","author":"M Moehler","year":"2016","unstructured":"Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, et al. Immunotherapy in gastrointestinal cancer: recent results, current studies and future perspectives. Eur J Cancer. 2016;59:160\u201370. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2016.02.020\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"26","key":"836_CR10","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1200690\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"836_CR11","doi-asserted-by":"publisher","unstructured":"Bilgin B, Sendur MA, Bulent Akinci M, Sener Dede D, Yalcin B. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Curr Med Res Opin. 2017:1\u201311. \n                    https:\/\/doi.org\/10.1080\/03007995.2017.1279132\n                    \n                  .","DOI":"10.1080\/03007995.2017.1279132"},{"key":"836_CR12","unstructured":"FDA approves Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) for previously treated patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer whose tumors express PD-L1 (CPS greater than or equal to 1). Merck. 2017. \n                    http:\/\/bit.ly\/2wberGs\n                    \n                  . Accessed 5 May 2018."},{"issue":"15_suppl","key":"836_CR13","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/JCO.2017.35.15_suppl.4003","volume":"35","author":"CS Fuchs","year":"2017","unstructured":"Fuchs CS, Doi T, Jang RW-J, Muro K, Satoh T, Machado M, et al. KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. J Clin Oncol. 2017;35(15_suppl):4003. \n                    https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.4003\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"836_CR14","unstructured":"FDA grants accelerated approval to pembrolizumab for tissue\/site agnostic indication. US FDA web site. 2017. \n                    https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm560040.htm\n                    \n                  . Accessed 5 May 2018."},{"key":"836_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ejca.2017.09.021","volume":"86","author":"A Baraniskin","year":"2017","unstructured":"Baraniskin A, Van Laethem JL, Wyrwicz L, Guller U, Wasan HS, Matysiak-Budnik T, et al. Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)\/World Congress on Gastrointestinal Cancer, Barcelona. Eur J Cancer. 2017;86:305\u201317. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2017.09.021\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"7517","key":"836_CR16","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"TCGA","year":"2014","unstructured":"TCGA. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. \n                    https:\/\/doi.org\/10.1038\/nature13480\n                    \n                  .","journal-title":"Nature"},{"issue":"3","key":"836_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/modpathol.2016.202","volume":"30","author":"R Saito","year":"2016","unstructured":"Saito R, Abe H, Kunita A, Yamashita H, Seto Y, Fukayama M. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein\u2013Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol. 2016;30(3):427\u201339. \n                    https:\/\/doi.org\/10.1038\/modpathol.2016.202\n                    \n                  .","journal-title":"Mod Pathol"},{"issue":"1","key":"836_CR18","doi-asserted-by":"publisher","first-page":"e1249558","DOI":"10.1080\/2162402X.2016.1249558","volume":"6","author":"S Su","year":"2017","unstructured":"Su S, Zou Z, Chen F, Ding N, Du J, Shao J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer. Oncoimmunology. 2017;6(1):e1249558. \n                    https:\/\/doi.org\/10.1080\/2162402x.2016.1249558\n                    \n                  .","journal-title":"Oncoimmunology"},{"issue":"6349","key":"836_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409\u201313. \n                    https:\/\/doi.org\/10.1126\/science.aan6733\n                    \n                  .","journal-title":"Science"},{"issue":"3","key":"836_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00428-009-0813-z","volume":"455","author":"E Solcia","year":"2009","unstructured":"Solcia E, Klersy C, Mastracci L, Alberizzi P, Candusso ME, Diegoli M, et al. A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis. Virchows Arch. 2009;455(3):197\u2013211. \n                    https:\/\/doi.org\/10.1007\/s00428-009-0813-z\n                    \n                  .","journal-title":"Virchows Arch"},{"issue":"7","key":"836_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/01.MP.0000076980.73826.C0","volume":"16","author":"KL Grogg","year":"2003","unstructured":"Grogg KL, Lohse CM, Pankratz VS, Halling KC, Smyrk TC. Lymphocyte-rich gastric cancer: associations with Epstein\u2013Barr virus, microsatellite instability, histology, and survival. Mod Pathol. 2003;16(7):641\u201351. \n                    https:\/\/doi.org\/10.1097\/01.mp.0000076980.73826.c0\n                    \n                  .","journal-title":"Mod Pathol"},{"issue":"4","key":"836_CR22","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","volume":"46","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein\u2013Barr virus and gastric cancer (review). Int J Oncol. 2015;46(4):1421\u201334. \n                    https:\/\/doi.org\/10.3892\/ijo.2015.2856\n                    \n                  .","journal-title":"Int J Oncol"},{"issue":"26","key":"836_CR23","first-page":"1214","volume":"46","author":"HH Wang","year":"1999","unstructured":"Wang HH, Wu MS, Shun CT, Wang HP, Lin CC, Lin JT. Lymphoepithelioma-like carcinoma of the stomach: a subset of gastric carcinoma with distinct clinicopathological features and high prevalence of Epstein\u2013Barr virus infection. Hepatogastroenterology. 1999;46(26):1214\u20139.","journal-title":"Hepatogastroenterology"},{"issue":"5","key":"836_CR24","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2559.2004.01998.x","volume":"45","author":"BJ Lu","year":"2004","unstructured":"Lu BJ, Lai M, Cheng L, Xu JY, Huang Q. Gastric medullary carcinoma, a distinct entity associated with microsatellite instability-H, prominent intraepithelial lymphocytes and improved prognosis. Histopathology. 2004;45(5):485\u201392. \n                    https:\/\/doi.org\/10.1111\/j.1365-2559.2004.01998.x\n                    \n                  .","journal-title":"Histopathology"},{"issue":"1","key":"836_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/1097-0142(197607)38:1<232::AID-CNCR2820380135>3.0.CO;2-4","volume":"38","author":"H Watanabe","year":"1976","unstructured":"Watanabe H, Enjoji M, Imai T. Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer. 1976;38(1):232\u201343.","journal-title":"Cancer"},{"key":"836_CR26","volume-title":"WHO classification of tumours of the digestive system","author":"FT Bosman","year":"2010","unstructured":"Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010."},{"issue":"10","key":"836_CR27","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.molonc.2016.09.004","volume":"10","author":"C Dai","year":"2016","unstructured":"Dai C, Geng R, Wang C, Wong A, Qing M, Hu J, et al. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. 2016;10(10):1551\u20138. \n                    https:\/\/doi.org\/10.1016\/j.molonc.2016.09.004\n                    \n                  .","journal-title":"Mol Oncol"},{"key":"836_CR28","doi-asserted-by":"publisher","unstructured":"Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein\u2013Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer (Serial Online). 2016. \n                    https:\/\/doi.org\/10.1007\/s10120-016-0631-3\n                    \n                  . \n                    http:\/\/link.springer.com\n                    \n                  . Accessed 9 Apr 2017.","DOI":"10.1007\/s10120-016-0631-3"},{"key":"836_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.humpath.2016.05.012","volume":"55","author":"Z Li","year":"2016","unstructured":"Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol. 2016;55:182\u201389. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2016.05.012\n                    \n                  .","journal-title":"Hum Pathol"},{"issue":"5","key":"836_CR30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","volume":"66","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794\u2013801. \n                    https:\/\/doi.org\/10.1136\/gutjnl-2015-310839\n                    \n                  .","journal-title":"Gut"},{"issue":"22","key":"836_CR31","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","volume":"7","author":"S Derks","year":"2016","unstructured":"Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, et al. Abundant PD-L1 expression in Epstein\u2013Barr virus-infected gastric cancers. Oncotarget. 2016;7(22):32925\u201332. \n                    https:\/\/doi.org\/10.18632\/oncotarget.9076\n                    \n                  .","journal-title":"Oncotarget"},{"key":"836_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.humpath.2016.02.007","volume":"53","author":"M Dong","year":"2016","unstructured":"Dong M, Wang HY, Zhao XX, Chen JN, Zhang YW, Huang Y, et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein\u2013Barr virus-associated gastric carcinoma. Hum Pathol. 2016;53:25\u201334. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2016.02.007\n                    \n                  .","journal-title":"Hum Pathol"},{"issue":"11","key":"836_CR33","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","volume":"40","author":"C Ma","year":"2016","unstructured":"Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein\u2013Barr virus or microsatellite instability. Am J Surg Pathol. 2016;40(11):1496\u2013506. \n                    https:\/\/doi.org\/10.1097\/pas.0000000000000698\n                    \n                  .","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"836_CR34","doi-asserted-by":"publisher","first-page":"24269","DOI":"10.18632\/oncotarget.8169","volume":"7","author":"C Boger","year":"2016","unstructured":"Boger C, Behrens HM, Mathiak M, Kruger S, Kalthoff H, Rocken C. PD-L1 is an independent prognostic predictor in gastric cancer of western patients. Oncotarget. 2016;7(17):24269\u201383. \n                    https:\/\/doi.org\/10.18632\/oncotarget.8169\n                    \n                  .","journal-title":"Oncotarget"},{"issue":"7","key":"836_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/modpathol.2016.55","volume":"29","author":"N Setia","year":"2016","unstructured":"Setia N, Agoston AT, Han HS, Mullen JT, Duda DG, Clark JW, et al. A protein and mRNA expression-based classification of gastric cancer. Mod Pathol. 2016;29(7):772\u201384. \n                    https:\/\/doi.org\/10.1038\/modpathol.2016.55\n                    \n                  .","journal-title":"Mod Pathol"},{"issue":"1","key":"836_CR36","doi-asserted-by":"publisher","first-page":"e000009","DOI":"10.1136\/esmoopen-2015-000009","volume":"1","author":"K Das","year":"2016","unstructured":"Das K, Chan XB, Epstein D, Teh BT, Kim K-M, Kim ST, et al. NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open. 2016;1(1):e000009. \n                    https:\/\/doi.org\/10.1136\/esmoopen-2015-000009\n                    \n                  .","journal-title":"ESMO Open"},{"key":"836_CR37","unstructured":"R Core Team (2013). R: a language and environment for statistical computing.\u00a0Vienna, Austria : the R Foundation for Statistical Computing.\u00a0\n                    http:\/\/www.R-project.org\/\n                    \n                  . Accessed 5 May 2018."},{"issue":"7637","key":"836_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. \n                    https:\/\/doi.org\/10.1038\/nature21349\n                    \n                  .","journal-title":"Nature"},{"issue":"2","key":"836_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jss.2014.12.005","volume":"194","author":"S Park","year":"2015","unstructured":"Park S, Choi MG, Kim KM, Kim HS, Jung SH, Lee JH, et al. Lymphoepithelioma-like carcinoma: a distinct type of gastric cancer. J Surg Res. 2015;194(2):458\u201363. \n                    https:\/\/doi.org\/10.1016\/j.jss.2014.12.005\n                    \n                  .","journal-title":"J Surg Res"},{"issue":"2","key":"836_CR40","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s10120-014-0376-9","volume":"18","author":"N Cheng","year":"2015","unstructured":"Cheng N, Hui DY, Liu Y, Zhang NN, Jiang Y, Han J, et al. Is gastric lymphoepithelioma-like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms. Gastric Cancer. 2015;18(2):246\u201355. \n                    https:\/\/doi.org\/10.1007\/s10120-014-0376-9\n                    \n                  .","journal-title":"Gastric Cancer"},{"key":"836_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jss.2016.11.012","volume":"210","author":"M Ramos","year":"2017","unstructured":"Ramos M, Pereira MA, Dias AR, Faraj SF, Zilberstein B, Cecconello I, et al. Lymphoepithelioma-like gastric carcinoma: clinicopathological characteristics and infection status. J Surg Res. 2017;210:159\u201368. \n                    https:\/\/doi.org\/10.1016\/j.jss.2016.11.012\n                    \n                  .","journal-title":"J Surg Res"},{"issue":"4","key":"836_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306. \n                    https:\/\/doi.org\/10.1038\/nrc3245\n                    \n                  .","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"836_CR43","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.cgh.2015.04.015","volume":"13","author":"H Lim","year":"2015","unstructured":"Lim H, Park YS, Lee JH, Son da H, Ahn JY, Choi KS, et al. Features of gastric carcinoma with lymphoid stroma associated with Epstein\u2013Barr virus. Clin Gastroenterol Hepatol. 2015;13(10):1738\u201344. \n                    https:\/\/doi.org\/10.1016\/j.cgh.2015.04.015\n                    \n                  .","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"836_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1046\/j.1365-2559.2000.01014.x","volume":"37","author":"MS Chang","year":"2000","unstructured":"Chang MS, Kim WH, Kim CW, Kim YI. Epstein\u2013Barr virus in gastric carcinomas with lymphoid stroma. Histopathology. 2000;37(4):309\u201315.","journal-title":"Histopathology"},{"issue":"2","key":"836_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s004280100441","volume":"439","author":"AM Chiaravalli","year":"2001","unstructured":"Chiaravalli AM, Cornaggia M, Furlan D, Capella C, Fiocca R, Tagliabue G, et al. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage. Virchows Arch. 2001;439(2):158\u201369.","journal-title":"Virchows Arch"},{"issue":"9","key":"836_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.prp.2011.07.004","volume":"207","author":"M Fukayama","year":"2011","unstructured":"Fukayama M, Ushiku T. Epstein\u2013Barr virus-associated gastric carcinoma. Pathol Res Pract. 2011;207(9):529\u201337. \n                    https:\/\/doi.org\/10.1016\/j.prp.2011.07.004\n                    \n                  .","journal-title":"Pathol Res Pract"},{"key":"836_CR47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-2211","author":"BH Sohn","year":"2017","unstructured":"Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ, et al. Clinical significance of four molecular subtypes of gastric cancer identified by The Cancer Genome Atlas Project. Clin Cancer Res Off J Am Assoc Cancer Res. 2017. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-2211\n                    \n                  .","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"836_CR48","doi-asserted-by":"publisher","first-page":"e1356150","DOI":"10.1080\/2162402X.2017.1356150","volume":"6","author":"C Park","year":"2017","unstructured":"Park C, Cho J, Lee J, Kang SY, An JY, Choi MG, et al. Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. Oncoimmunology. 2017;6(11):e1356150. \n                    https:\/\/doi.org\/10.1080\/2162402x.2017.1356150\n                    \n                  .","journal-title":"Oncoimmunology"},{"issue":"1","key":"836_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43\u201351. \n                    https:\/\/doi.org\/10.1158\/2159-8290.cd-14-0863\n                    \n                  .","journal-title":"Cancer Discov"},{"issue":"3","key":"836_CR50","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/humu.22014","volume":"33","author":"W Wang","year":"2012","unstructured":"Wang W, Sun J, Li F, Li R, Gu Y, Liu C, et al. A frequent somatic mutation in CD274 3\u2032-UTR leads to protein over-expression in gastric cancer by disrupting miR-570 binding. Hum Mutat. 2012;33(3):480\u20134. \n                    https:\/\/doi.org\/10.1002\/humu.22014\n                    \n                  .","journal-title":"Hum Mutat"},{"issue":"6","key":"836_CR51","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00439-013-1275-6","volume":"132","author":"W Wang","year":"2013","unstructured":"Wang W, Li F, Mao Y, Zhou H, Sun J, Li R, et al. A miR-570 binding site polymorphism in the B7-H1 gene is associated with the risk of gastric adenocarcinoma. Hum Genet. 2013;132(6):641\u20138. \n                    https:\/\/doi.org\/10.1007\/s00439-013-1275-6\n                    \n                  .","journal-title":"Hum Genet"},{"issue":"7607","key":"836_CR52","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","volume":"534","author":"K Kataoka","year":"2016","unstructured":"Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, et al. Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature. 2016;534(7607):402\u20136. \n                    https:\/\/doi.org\/10.1038\/nature18294\n                    \n                  .","journal-title":"Nature"},{"issue":"18","key":"836_CR53","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767\u201378. \n                    https:\/\/doi.org\/10.1056\/NEJMra1514296\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"200","key":"836_CR54","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3006504\n                    \n                  .","journal-title":"Sci Transl Med"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10120-018-0836-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-018-0836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-018-0836-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T04:45:06Z","timestamp":1568954706000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10120-018-0836-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,19]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["836"],"URL":"https:\/\/doi.org\/10.1007\/s10120-018-0836-8","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,19]]},"assertion":[{"value":"16 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"This was a retrospective study and, accordingly, the authors were not expected to have consent to participate. Ethics approval was obtained (CES 236-14). No potentially identifiable patient images or data were included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}